Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Pili on Significance of Entinostat/IL-2 Study in RCC

Roberto Pili, MD
Published: Wednesday, May 25, 2016


Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.

Out of the 41 evaluable patients with measurable disease, a 37% overall response rate was observed with the combination. Three patients achieved complete remissions and 12 patients achieved objective response.

To date, in patients treated with the combination of entinostat and IL-2, the median progression-free survival was 16.1 months and an overall survival of 65.3 months.

Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.

Out of the 41 evaluable patients with measurable disease, a 37% overall response rate was observed with the combination. Three patients achieved complete remissions and 12 patients achieved objective response.

To date, in patients treated with the combination of entinostat and IL-2, the median progression-free survival was 16.1 months and an overall survival of 65.3 months.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x